| 摘要 |
<p>Disclosed is the use of an isolated lysyl oxidase-related-2 (LOXL2) inhibitor in the manufacture of a medicament for the prevention of, treatment of, or reversing a symptom of a pulmonary fibrotic disorder in a subject, wherein the inhibitor is an antibody that specifically binds to a LOXL2 protein, and prevents an increase in or decreases pulmonary leukocyte number in the subject.</p> |
